NCT02280837View on ClinicalTrials.gov

Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?

CompletedOBSERVATIONAL
Enrollment

190

Participants

Timeline

Start Date

February 27, 2015

Primary Completion Date

March 27, 2019

Study Completion Date

December 29, 2020

Conditions
Coronary Artery Disease
Interventions
OTHER

Determination of plasma GLP-1 level

Determination of GLP-1 level in samples of oral glucose tolerance tests

Trial Locations (1)

0608556

Sapporo Medical University, School of Medicine, Sapporo

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sapporo Medical University

OTHER

NCT02280837 - Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease? | Biotech Hunter | Biotech Hunter